England begins mass NHS rollout of tirzepatide through GPs

Starting Monday, June 23, 2025, general practitioners across England were allowed for the first time to prescribe tirzepatide, sold in the UK as Mounjaro, to eligible patients ^[1]. The National Health Service expects about 220,000 people with the "greatest need" to receive the drug over the next three years ^[1]. Before this change, patients could only get the medicine through specialist weight-loss clinics ^[1].

In the first year, the drug will go to people with a body mass index over 40 who also have at least four other health conditions linked to obesity, such as type 2 diabetes, high blood pressure, heart disease, or obstructive sleep apnoea ^[1]. Tirzepatide is made by Eli Lilly and works by lowering blood sugar and slowing digestion ^[1]. The Guardian reports that an estimated 1.5 million people in the UK are already taking weight-loss drugs, whether through specialist NHS services or private prescriptions ^[1].

The rollout has raised concerns among doctors and pharmacists. Prof Kamila Hawthorne, chair of the Royal College of GPs, said many family doctors worry about the added workload and training needed to safely start and manage patients on these drugs, given that general practice is already under "intense workload and workforce pressures" ^[1]. She also cautioned that weight-loss medications "mustn't be seen as a 'silver bullet'" and said more attention is needed on preventing obesity in the first place ^[1].

Olivier Picard, chair of the National Pharmacy Association, said demand for weight-loss injections keeps rising sharply and that prescription volumes are expected to increase rapidly as NHS guidance takes effect ^[1]. He predicted that NHS supply "won't meet demand straight away," so many people will keep buying the drug privately from pharmacies even after the public rollout begins ^[1].

Why it matters for patients

For American readers, the UK coverage can be confusing because of branding. In the United States, tirzepatide is sold under two different names depending on the use: Mounjaro for type 2 diabetes and Zepbound for weight loss. The UK has no separate weight-loss brand, so British outlets, including the source for this story, refer to the drug simply as Mounjaro even when it is being used for weight management ^[1]. That means a headline about "Mounjaro" in a British newspaper may describe exactly the kind of use Americans associate with Zepbound.

The NHS system itself also works differently from US insurance. In England, GPs decide who qualifies based on national clinical criteria, such as the BMI and comorbidity thresholds described here, rather than through private insurance formularies or employer plans common in the US ^[1]. The rollout does not change how tirzepatide is prescribed, priced, or covered in the United States. It also does not indicate anything new about the safety or effectiveness of the drug beyond what has already been established for prescribing decisions.

What happens next

The NHS plans to expand access to the roughly 220,000 patients over three years, expanding eligibility criteria over time ^[1]. Because supply is expected to lag behind demand, at least in the near term, pharmacy leaders anticipate many UK patients will continue seeking the drug through private prescriptions rather than through the NHS program alone ^[1].